GILD is the most undervalued stock in the biotech space and is making up for dwindling growth by aggressively buying back stock. Last year GILD bought back $15 billion worth of shares and plans to repurchase another $12 billion worth in 2016. Has the money to keep on buying back shares at a rate that gives earnings per share a 10% or more hike annually, a good buy for a stock trading at only 7 times earnings.
GILD is like APPL. They have all the money in the world but can't seem to make an acquisition that would reverse the slide from the slowing down of their biggest money-makers. Until they do, we'll continue to lose money on them. I don't blame people for feeling frustrated.